Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc > Event Materials

<< Previous

Bullboard Posts

Next >>

Post by Sharecropper1on Aug 16, 2017 10:58am

133 Views

Post# 26587334

Event Materials

Alison is putting out a release of the deck used at the meeting. Should be out today. Apparently a 2.5M Pvt. Placement one share, one warrant, close Sept. 7th.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China